NCT07309159Not yet recruitingPhase 1/2
Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
This study aims to examine the dual effects of cannabis consumption on both positive and negative symptoms of schizophrenia, across laboratory and real-world contexts. By integrating ecological momentary assessment (EMA) with cognitive tasks such as reality monitoring, the research seeks to clarify how cannabis use influences symptom severity and cognitive functioning in individuals with schizophrenia. Gaining insight into these relationships may contribute to the development of more effective management strategies and ultimately improve outcomes for patients living with schizophrenia.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 24 Nov 2025
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
- Diseases
- Schizophrenia
- NCT number
- NCT07309159
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 120
- From 1 Jun 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychiatric comorbidities: autism, bipolar disorder.
- Current criteria for any other substance use disorder except for nicotine use disorder.
- Any medical condition hindering the study and/or use of the smartphone application.
- Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….).
Other
- Patient under "tutelle" (full legal guardianship).
- Pregnant or breastfeeding woman.
- Patients who are not proficient in French.
- Subject included in clinical and/or therapeutic experimentation in progress.
Who the study is looking for
- DSM-5 diagnosis of schizophrenia or schizo-affective disorder with the following clinical features:
- Clinically stable and in the residual (non-acute) phase of illness,
- No change in antipsychotic treatment for at least 1 month,
- Outpatient, ambulatory care,
- No uncontrolled positive symptoms (assessed using PANSS)
- Patients able to use a mobile phone.
- Capacity and willingness to give informed consent.
- Must be able to read, speak, and understand French
- Patients subscribing to the French national medical insurance.
- Patients under "curatelle" (partial guardianship) are eligible
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.